Zymeworks BC Inc (ZYME)

NASD · Healthcare · Biotechnology · USA

Zymeworks BC Inc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.

Zymeworks is a biotechnology company developing multifunctional biotherapeutics for cancer, inflammation, and autoimmune disease. The company manages a portfolio of licensed healthcare assets through partnerships with organizations like Jazz Pharmaceuticals and Johnson & Johnson, generating milestone payments and royalties. Its pipeline includes proprietary multispecific antibody therapeutics and antibody-drug conjugates, with wholly-owned candidates targeting solid tumors and inflammatory conditions.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Zymeworks BC Inc stock.

Our verdict on ZYME

Overvalued: intrinsic value $3.64 per share, market price $25.84, margin of safety -609.0% (as of 2026-11-17).

Discounting its cash flows at 10.1% (average of 2 methods) values the shares at $3.64; the price of $25.84 is 609% above that value, and 72% of that value comes from beyond year five.

ETFs with the most weight in ZYME

17 more funds hold it; the full list is part of the paid plan.

More on ZYME

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than ZYME in Biotechnology

97 more in this industry show a wider margin of safety.

Is ZYME undervalued or overvalued?

ZYME is overvalued (as of the 2026-11-17 close). Discounting its cash flows at 10.1% (average of 2 methods) values the shares at $3.64; the price of $25.84 is 609% above that value, and 72% of that value comes from beyond year five.

What is the intrinsic value of ZYME?

$3.64 per share (as of the 2026-11-17 close), against a market price of $25.84. That is a margin of safety of -609.0%. The value is the average of the 2 valuation methods that apply to this company, recomputed every night after the US close.